KUNMING LONGJIN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.87 CNY | +2.09% |
|
+2.09% | -41.30% |
| Sales 2022 | 123M 16.99M 23.29M | Sales 2023 | 86.62M 11.97M 16.41M | Capitalization | 4B 553M 759M |
|---|---|---|---|---|---|
| Net income 2022 | -56M -7.74M -10.61M | Net income 2023 | -70M -9.67M -13.26M | EV / Sales 2022 | 33 x |
| Net cash position 2022 | 403M 55.69M 76.38M | Net cash position 2023 | 333M 46.02M 63.11M | EV / Sales 2023 | 42.4 x |
| P/E ratio 2022 |
-79.4
x | P/E ratio 2023 |
-56.5
x | Employees | 262 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 41.99% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.09% | ||
| 1 week | +2.09% | ||
| Current month | -21.52% | ||
| 1 month | -21.52% | ||
| 3 months | -33.82% | ||
| 6 months | -43.34% | ||
| Current year | -41.30% |
1 week
5.55
6.02
1 month
5.557.88
Current year
4.6611.50
1 year
4.6612.50
3 years
4.6624.33
5 years
4.6624.33
10 years
4.6626.55
| Managers | Title | Age | Since |
|---|---|---|---|
Xian E Fan
FOU | Founder | 72 | 96-09-15 |
Li Juan Fan
CEO | Chief Executive Officer | 38 | 16-01-31 |
Ping Liu
CHM | Chairman | 48 | 08-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xian E Fan
FOU | Founder | 72 | 96-09-15 |
Xiao Nan Zhou
BRD | Director/Board Member | 65 | 08-07-27 |
Ya He Li
BRD | Director/Board Member | 50 | 02-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 5.87 | +2.09% | 12,311,670 |
| 24-04-26 | 5.75 | -1.37% | 10,827,430 |
| 24-04-25 | 5.83 | +1.92% | 8,179,700 |
| 24-04-24 | 5.72 | +1.42% | 5,955,200 |
| 24-04-23 | 5.64 | -1.91% | 9,151,201 |
End-of-day quote Shenzhen S.E., April 28, 2024
More quotes
Kunming Longjin Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and sales of natural botanical and chemical lyophilized powder injection. The Company's products cover traditional Chinese medicine, biochemical medicine and chemical medicine, which including cardio-cerebral vascular medicine, digestive system medicine, immune system medicine, vitamins, mineral enteral and parenteral nutrition medicines. The main products of which is breviscapine injection. The Company conducts its businesses primarily within the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -41.30% | 325M | |
| +20.61% | 43.18B | |
| +20.67% | 22.59B | |
| +15.19% | 14.56B | |
| +13.94% | 13.54B | |
| +43.35% | 11.5B | |
| -8.37% | 6.93B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.36B |
- Stock Market
- Equities
- 002750 Stock
